Pyc Therapeutics Limited · ASX:PYC

Pyc Therapeutics — Phylogica — BioSquare Geneva (March 2006)

21 slides from Pyc Therapeutics's conference presentation, Mar 10, 2006

  1. Slide 1: Dr Stewart Washer, Chief Executive Officer, BioSquare

    Dr Stewart Washer Chief Executive Officer BioSquare March, 2006

  2. Slide 2: Opportunities Beyond Antibodies

    ng Opportunities yond Antibodies rvice evelopment for validated inflammatory disease _ drug candidates YLOGICA OND BH TIPOOLES

  3. Slide 3: Corporate Overview

    ate Overview Major Shareholders ~~ Biotech Capital Ltd: 26.9% Institute for Child Research: 19.0% -Dr Paul Watt -: oe 3.7% ‘Share Price and Volume Past 6 months HYLOGICA EYORD AB TIBODIES

  4. Slide 4: rty is wholly owned by Phyl

    rty is wholly owned by Phyl nt. HYLOGICA MD AUTO UIES

  5. Slide 5: Phylomer libraries versus other libraries

    d (1000-5000 classes of fold) libraries are based on.a single class “Multiple Natural Scaitolde Slagle Artificial Scalfold sm} 1s provide. HYLOGICA EYORD AB TIBODIES

  6. Slide 6: Phylomer Technology

    lomer®. Technology Rekerya Haterptelion sap EPO Poenet ene inane Cates Plageltetes Prlaheontenaady Eeetarematvxe ‘area scanealtior fac beirie Wileranpeertetios Tiphoceenacte arts of proteins) of peptide shape HYLOGICA OND BH TIPOOLES

  7. Slide 7: Commercial Proposition

    cial Proposition syond antibodies act replacement generation ery potential. HYLOGICA EYORD AB TIBODIES

  8. Slide 8: BOBBBBee T

    BOBBBBee T YLOGICA OND BH TIPOOLES

  9. Slide 9: Stroke: preventing cell death around the initial event

    rrounding the initial event die sts. to prevent this cell death and g astroke : Impairment of function (penumbra) Structural lesion YLOGICA YOUD ANTIBODIES

  10. Slide 10: Cell death completely prevented in stroke and Alzheimer model

    completely prevented stroke and Alzheimer.model EYORD AB TIBODIES

  11. Slide 11: Apoptosis

    optosis: mia model. P34 YLOGICA YOUD ANTIBODIES

  12. Slide 12: Response PYC36S

    YLOGICA WANS wpswiz ees WPAN" foes: Response PYC36S

  13. Slide 13: Burns

    Burns leading cause of accidental arto the damage following a HYLOGICA YOMD AB TIBOUIES

  14. Slide 14: Burns

    Burns executed with Dr Fiona Wood date PYC35B has demonstrated model Me YLOGICA OND BH TIPOOLES

  15. Slide 15: Burns: Day 1

  16. Slide 16: HYLOGICA

    HYLOGICA MO BO

  17. Slide 17: HYLOGICA

    ee HYLOGICA MO BO

  18. Slide 18: Burns: Day 11

  19. Slide 19: Burns

    Burns of treated mice showed; mation ~ rlier in healing time YLOGICA OND BH TIPOOLES

  20. Slide 20: Beyond Antibodies

    eyond Antibodies re deliverable — elopment for validated targets HYLOGICA EYORD AB TIBODIES

  21. Slide 21: Phylogica Limited

    a Limited ond Antibodies YLOGICA YOUD ANTIBODIES

Phylogica — BioSquare Geneva (March 2006) on 6ix